Since its inception, MSCRF has invested over $170 million in over 500 projects to accelerate stem cell research, commercialization, and cures. With a 2023 fiscal year budget of $20.5M, MSCRF offers six funding opportunities to scientists and companies in the areas of clinical trials, discovery, commercialization, validation, launch, and post-doctoral fellowships. The fund has supported the creation and growth of many stem cell companies since launching the Accelerating Cures initiative in 2017.
The Crab Trap competition brings together entrepreneurs with innovative diagnostics, medical devices, therapeutics or other transformative health solutions to compete for a prize package valued at $50,000, which includes cash rewards and a one-year residency at JLABS @ Washington DC. Crab Trap finalists will earn the chance to make an in-person pitch at the BioHealth Region Investment Conference.
This is Part Two of our series on the vibrant Baltimore medtech ecosystem gaining significant momentum in Baltimore. Part One featured five exciting companies, including CoapTech, JuneBrain, ClearMask, LifeSprout, and NextStep Robotics.
BioBuzz has been reporting on myriad medtech university system spinouts and maturing companies from the Baltimore area for a number of years; we’ve featured a number of exciting and promising individual companies. However, as we’ve stepped back a bit to examine more recent Baltimore biohub developments, it’s become clear that there is an unmistakable groundswell of medtech activity that’s transforming the Baltimore life sciences sector.
The Baltimore biotech ecosystem is thriving. And new, big and bold life sciences development projects are in the works, leading many to project Charm City as the next sector of the BioHealth Capital Region (BHCR) to boom.
BALTIMORE–(BUSINESS WIRE)–LifeSprout, Inc., a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced the appointment of Michael Kranda as CEO and member of the board of directors.
“We’re pleased to have attracted an executive of Michael’s caliber to lead LifeSprout at this pivotal time for the company as we proceed to leverage the full potential of our regenerative cell therapy platform,” said Sashank Reddy, M.D., Ph.D., co-founder of LifeSprout.
“I welcome the opportunity to lead the LifeSprout team, and collaborate with the thought leaders in tissue engineering, nano biotechnology, and materials science from Johns Hopkins to establish a new standard of bio stimulatory products for cell therapy applications,” said Kranda, LifeSprout, Inc. CEO.
Johns Hopkins Technology Ventures (JHTV) has had a significant impact on the Maryland life sciences ecosystem since its founding in 2014, assisting with hundreds of licensed therapeutics in development and backing nearly 200 startups that have collectively nearly $3 billion in venture capital funding, 30% of which has remained in the state.
End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region
This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.
2020 Life Science Venture Capital Funding Roundup for Q1/Q2 in the BioHealth Capital Region BioHealth Companies raised more than $178M in the first half of 2020 June 9, 2020 This [….]
Baltimore, Maryland’s LifeSprout Closes $28.5M Series-A, Looks Toward the Future LifeSprout, a privately-held regenerative medicine company located in Baltimore, Maryland, recently announced the closing of a $28.5M Series A financing [….]